Immunotherapy for metastatic renal cell carcinoma

The Cochrane Database of Systematic Reviews
Susanne UnverzagtBarbara Seliger

Abstract

Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm shift from non-specific therapy with broad-acting cytokines to specific regimens, which directly target the cancer, the tumour microenvironment, or both.Current guidelines recommend targeted therapies with agents such as sunitinib, pazopanib or temsirolimus (for people with poor prognosis) as the standard of care for first-line treatment of people with mRCC and mention non-specific cytokines as an alternative option for selected patients.In November 2015, nivolumab, a checkpoint inhibitor directed against programmed death-1 (PD-1), was approved as the first specific immunotherapeutic agent as second-line therapy in previously treated mRCC patients. To assess the effects of immunotherapies either alone or in combination with standard targeted therapies for the treatment of metastatic renal cell carcinoma and their efficacy to maximize patient benefit. We searched the Cochrane Library, MEDLINE (Ovid), Embase (Ovid), ISI Web of Science and registers of ongoing clinical trials in November 2016 without language restrictions. We scanned reference lists and contacted experts in the field to obtain further information. We included random...Continue Reading

References

Apr 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S D FossåE E Holdener
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R WeissM H Bar
Dec 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T CreaganD H Gesme
May 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A NeidhartR L Tuttle
Dec 1, 1990·Journal of Interferon Research·E C BordenA P Teitelbaum
Aug 1, 1985·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·F EdsmyrH Strander
Aug 1, 1989·American Journal of Clinical Oncology·F H DexeusL Finn
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H B MussM S Mitchell
Nov 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R QuesadaJ U Gutterman
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsR Gucalp
Dec 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SagasterH Ludwig
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Sep 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·R G FentonD L Longo
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B EscudierS Négrier
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A FiglinA S Belldegrun
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PyrhönenP L Kellokumpu-Lehtinen
Jul 25, 2000·The Cochrane Database of Systematic Reviews·C CoppinT Wilt
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerM Mazumdar
Aug 24, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·N TsavarisP Kosmidis
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G PizzocaroE Marubini
May 22, 2001·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·R J MotzerR M Bukowski
Oct 5, 2001·Lancet·G H MickischUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson

❮ Previous
Next ❯

Citations

Jun 8, 2019·Expert Opinion on Biological Therapy·Iris Y Sheng, Brian I Rini
Oct 16, 2020·The Cochrane Database of Systematic Reviews·Fabian HofmannBörje Ljungberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

The Cochrane Database of Systematic Reviews
Luciana ThiagoÁlvaro Nagib Atallah
São Paulo Medical Journal = Revista Paulista De Medicina
Luciana ThiagoÁlvaro Nagib Atallah
The Cochrane Database of Systematic Reviews
Tobias JakobMatthias Briel
The Cochrane Database of Systematic Reviews
Zhirong YangSiyan Zhan
© 2022 Meta ULC. All rights reserved